Correlation Between Replimune and Keros Therapeutics

Can any of the company-specific risk be diversified away by investing in both Replimune and Keros Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Replimune and Keros Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Replimune Group and Keros Therapeutics, you can compare the effects of market volatilities on Replimune and Keros Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Replimune with a short position of Keros Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Replimune and Keros Therapeutics.

Diversification Opportunities for Replimune and Keros Therapeutics

0.46

Correlation Coefficient

Replimune  Keros Therapeutics

Very weak diversification

The 3 months correlation between Replimune and Keros is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Replimune Group and Keros Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Keros Therapeutics and Replimune is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Replimune Group are associated (or correlated) with Keros Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Keros Therapeutics has no effect on the direction of Replimune i.e., Replimune and Keros Therapeutics go up and down completely randomly.

Pair Corralation between Replimune and Keros Therapeutics

Given the investment horizon of 90 days Replimune Group is expected to under-perform the Keros Therapeutics. In addition to that, Replimune is 1.45 times more volatile than Keros Therapeutics. It trades about 0.0 of its total potential returns per unit of risk. Keros Therapeutics is currently generating about 0.02 per unit of volatility. If you would invest  5,177  in Keros Therapeutics on September 3, 2024 and sell it today you would earn a total of  597.00  from holding Keros Therapeutics or generate 11.53% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Replimune Group  vs.  Keros Therapeutics

Replimune Group

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Replimune Group are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite quite conflicting basic indicators, Replimune disclosed solid returns over the last few months and may actually be approaching a breakup point.

Keros Therapeutics

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Keros Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Keros Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Replimune and Keros Therapeutics

The main advantage of trading using opposite Replimune and Keros Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Replimune position performs unexpectedly, Keros Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Keros Therapeutics will offset losses from the drop in Keros Therapeutics' long position.

The idea behind Replimune Group and Keros Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.